Vanda Pharmaceuticals (VNDA) Set to Announce Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA) will be releasing its earnings data after the market closes on Wednesday, February 14th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.11) per share for the quarter.

Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) opened at $15.65 on Wednesday. The stock has a market cap of $703.12, a price-to-earnings ratio of -48.91 and a beta of 1.23. Vanda Pharmaceuticals has a fifty-two week low of $11.90 and a fifty-two week high of $18.99.

Several brokerages have issued reports on VNDA. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, October 19th. Oppenheimer set a $26.00 target price on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, October 29th. Seaport Global Securities began coverage on shares of Vanda Pharmaceuticals in a report on Friday, January 19th. They issued a “buy” rating and a $20.00 target price on the stock. BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Finally, ValuEngine lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Vanda Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $21.29.

In related news, SVP Gunther Birznieks sold 8,568 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $15.26, for a total transaction of $130,747.68. Following the transaction, the senior vice president now owns 118,366 shares in the company, valued at approximately $1,806,265.16. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Mihael Hristos Polymeropoulos sold 191,760 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $15.30, for a total transaction of $2,933,928.00. Following the transaction, the insider now owns 1,031,848 shares in the company, valued at approximately $15,787,274.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 209,483 shares of company stock worth $3,205,205. 7.60% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This report was first published by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2018/02/07/vanda-pharmaceuticals-vnda-set-to-announce-earnings-on-wednesday.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply